01 — At a Glance
The Pain Business: Where Profits Hurt Less Than Stock Returns
- 52-Week High / Low₹127 / ₹57.5
- Q3 FY26 Revenue₹580 Cr
- Q3 FY26 PAT₹29 Cr
- TTM EPS₹3.96
- Annualised EPS (Q3 Avg × 4)₹2.80
- Book Value / Share₹59.7
- Price to Book1.24x
- ROCE8.86%
- Debt / Equity0.09x
- Return (3 Months)-13.7%
Flash Summary: IOL just delivered Q3 FY26 PAT of ₹29 crore — up 40.9% YoY. Revenue is up 10.9% at ₹580 crore. The company has near-zero debt (0.09x), generates ₹600+ crore in annual profits, and controls 35% of the global Ibuprofen market. Yet the stock trades at 18.2x P/E and has crashed 13.7% in three months. This is either a screaming bargain or investors are smarter than we think. Spoiler: probably both.
02 — Introduction
The Accidental Global Champion Nobody Talks About
There’s a small town called Barnala in Punjab. Population: around 100,000 humans. Chemical capacity: nearly 2 lakh metric tonnes per year. Since 1986, IOL Chemicals has been quietly building medicine in this town while the rest of India dreams about IPO riches and stock splits.
IOL is the largest manufacturer of Ibuprofen on Earth. Not India. Earth. 35% global market share. Every time your grandmother had a headache in Switzerland, or your cousin’s joint pain flared in Brazil, there’s a decent chance it was IOL’s Ibuprofen that saved the day. The company has zero debt (well, 0.09x), strong cash generation, and a business model that’s literally immune to economic slowdowns — people get sick and need medicine regardless of GDP growth.
The Q3 story is three-act play. Act 1: Revenue up 10.9%, PAT up 40.9%. Act 2: EBITDA margins expanded 100 basis points to 10.7%. Act 3: Share price down 13.7% in three months anyway. It’s like paying ₹1,000 for a perfectly cooked biryani and then complaining the restaurant didn’t give you a free dessert. Let’s break the paradox.
Concall Highlight (Feb 2026): Management said the primary margin driver was capacity utilization hitting 90-95% on Ibuprofen and nearly 100% on Ethyl Acetate. Translation: they’re running flat out and still making more profit. There’s no free lunch in manufacturing, but if you can run your factory at full capacity while competitors struggle, that’s as close as you get.
03 — Business Model: How a Town in Punjab Sells Pills to the World
Backward Integration Is Code for “We Control Our Own Destiny”
IOL makes two types of products: pharmaceuticals (59% of Q3 revenue) and chemicals (41%). In pharma, Ibuprofen is still the king at 64% of the pharma mix, but non-Ibuprofen APIs are growing fast at 36% of the pharma mix. In chemicals, Ethyl Acetate is the cash machine.
Here’s what makes IOL interesting: they don’t just make Ibuprofen. They make the stuff needed to make Ibuprofen. In their facility, Iso Butyl Benzene, Acetyl Chloride, Mono Chloro Acetic Acid — all made in-house. This is backward integration, and it’s like owning a rice farm, a flour mill, and a bakery all in one place. Your costs are locked. Your supply chain is locked. Your profits are locked in the cage only you have the key to.
The business operates across 80 countries. Exports are 24% of sales. The company has 18 CEP certifications (that’s European Pharmacopoeia approval — fancy validation that your medicine is legit). They’re adding new APIs — Minoxidil CEP was just granted in December 2025, and they’re targeting commercial launch in Q1 FY27 (April 2026). They diversified into a UK subsidiary in October 2025, because if your entire global pharma business runs from a Punjab town, eventually someone gets nervous and you need a European address.
Fun fact: IOL’s 17 MW captive power plant runs on coal and rice husk (yes, leftover agricultural waste). During Q2, rice husk prices were volatile, which squeezed margins slightly. By Q3, management said prices “almost stabilized.” Translation: the margin expansion in Q3 was partly because husk prices stopped punching them in the stomach. There’s poetry in that.
04 — Financials Overview
Q3 FY26: Revenue Up, Profit Way Up, But The Party Isn’t Universally Celebrated
Result type: Quarterly Results | Q3 FY26 EPS: ₹0.70 | Annualised EPS: ₹2.80
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 580 | 523 | 568 | +10.9% | +2.1% |
| Operating Profit | 57 | 47 | 57 | +21.3% | +0% |
| OPM % | 10% | 9% | 10% | +100 bps | flat |
| PAT | 21 | 15 | 30 | +40.9% | -30% |
| EPS (₹) | 0.70 | 0.50 | 1.02 | +40% | -31% |
The Sting: Revenue grew, profit grew, margins expanded. So why is PAT up 40.9% YoY but down 30% QoQ? Because Q2 had exceptional benefits — likely lower raw material costs from Q1 flooding aftermath, or one-time tax impacts. The management concall mentioned an ₹11.2 crore exceptional item in Q3 (labor law compliance provision). Strip that out, and normalized profit is cleaner. But investors see the drop QoQ and panic like a stock option holder at expiry.
💬 Q3 shows strong revenue growth and margin expansion, yet the stock tanked. Is this a case of “growth already priced in,” or are investors genuinely worried about capacity headwinds in Ibuprofen? Drop your theories in the comments.
05 — Valuation: Fair Value Range
Can You Really Put a Price on Owning 35% of Global Ibuprofen?
